A systematic review of the effectiveness of adalimumab

TABLE 67 Sensitivity analyses: TNF inhibitors in third place, late RA values
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
Scenario Adal – Base Etan – Base Adal+MTX – Etan+MTX – Infl+MTX –
Base Base Base
Base case 141,000 47,400 64,400 49,800 139,000
No HAQ progression on TNF inhibitors 41,500 24,400 30,200 24,600 39,400
Slow HAQ progression on all DMARDs 535,000 68,500 101,000 69,600 462,000
Slow HAQ progression on all treatments Base 90,200 150,000 93,300 Base
Fast HAQ progression on all treatments Base 95,400 147,000 96,100 Base
No effect of HAQ on mortality 97,700 43,300 53,800 43,900 92,900
Mortality ratio 2.73 per unit HAQ 680,000 53,000 84,400 53,400 329,000
Effectiveness of conventional DMARDs
down 50%
58,400 31,200 40,500 31,600 56,900
Effectiveness of conventional DMARDs
up 50%
Base 87,500 136,000 90,700 Base
Survival times on conventional DMARDs
down 50%
66,700 34,200 42,300 35,000 61,900
Survival times on conventional DMARDs
up 50%
324,000 57,900 84,600 59,700 246,000
Survival times on TNF inhibitors down 50% 120,000 46,400 62,300 46,600 124,000
Survival times on TNF inhibitors up 50% 149,000 47,700 63,200 48,900 130,000
Review at 12 weeks 145,000 47,000 62,800 48,200 125,000
Short-term quitters on TNF inhibitors
down 50%
134,000 45,800 64,200 48,800 115,000
Short-term quitters on TNF inhibitors
up 50%
151,000 47,100 59,400 48,100 135,000
Short-term quitters on conventional
DMARDs down 50%
165,000 48,900 60,700 48,700 132,000
Short-term quitters on conventional
DMARDs up 50%
99,200 42,800 55,600 43,800 94,600
Include offset costs 135,000 45,400 60,300 46,600 116,000
Base: baseline option dominates option with TNF inhibitor.
111